INNOVACAP Stock Overview
An integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Innova Captab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹978.55 |
| 52 Week High | ₹1,176.00 |
| 52 Week Low | ₹421.35 |
| Beta | 0 |
| 1 Month Change | 5.02% |
| 3 Month Change | 23.10% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 80.74% |
Recent News & Updates
Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding Innova Captab Limited's (NSE:INNOVACAP) Performance Completely
Aug 01
Innova Captab (NSE:INNOVACAP) Has A Pretty Healthy Balance Sheet
Jul 19We Think That There Are Issues Underlying Innova Captab's (NSE:INNOVACAP) Earnings
Jun 06What Innova Captab Limited's (NSE:INNOVACAP) P/E Is Not Telling You
May 21Shareholder Returns
| INNOVACAP | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -6.9% | -1.3% | -4.2% |
| 1Y | n/a | 49.7% | 19.1% |
Return vs Industry: Insufficient data to determine how INNOVACAP performed against the Indian Life Sciences industry.
Return vs Market: Insufficient data to determine how INNOVACAP performed against the Indian Market.
Price Volatility
| INNOVACAP volatility | |
|---|---|
| INNOVACAP Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: INNOVACAP has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INNOVACAP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,600 | Vinay Lohariwala | innovacaptab.com |
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals.
Innova Captab Limited Fundamentals Summary
| INNOVACAP fundamental statistics | |
|---|---|
| Market cap | ₹56.00b |
| Earnings (TTM) | ₹1.18b |
| Revenue (TTM) | ₹11.78b |
47.3x
P/E Ratio4.8x
P/S RatioIs INNOVACAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNOVACAP income statement (TTM) | |
|---|---|
| Revenue | ₹11.78b |
| Cost of Revenue | ₹7.83b |
| Gross Profit | ₹3.95b |
| Other Expenses | ₹2.76b |
| Earnings | ₹1.18b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.68 |
| Gross Margin | 33.51% |
| Net Profit Margin | 10.05% |
| Debt/Equity Ratio | 28.9% |
How did INNOVACAP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 12:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Innova Captab Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Amey Chalke | JM Financial Institutional Securities Limited |